Hologic Q1 Diagnostics Revenue Dips 1.3% to $464.4M as Molecular Sales Drop
Hologic’s Diagnostics revenue in Q1 fiscal 2026 fell 1.3% year-over-year to $464.4 million, led by a 3.5% decline in Molecular Diagnostics from weaker COVID-19 and legacy STI test sales. FDA approval for the Aptima HPV Assay and expanded CE marking for the Genius System strengthen its screening and imaging offerings.
1. Q1 Fiscal 2026 Diagnostics Revenue
Hologic’s Diagnostics segment generated $464.4 million in revenue in Q1 fiscal 2026, a 1.3% decrease year-over-year. The decline was primarily driven by lower COVID-19 test demand and reduced sales of legacy STI assays.
2. Molecular Diagnostics Performance
Molecular Diagnostics revenue fell 3.5% due to weaker COVID-19 and sexually transmitted infection test sales. Growth in BV, CV/TV assays and sales of Panther Fusion tests partially offset this shortfall.
3. Regulatory Approvals and Growth Drivers
FDA approval of the Aptima HPV Assay for primary screening and expanded CE marking for the Genius System in the EU enhance Hologic’s screening and imaging offerings. These regulatory wins support market diversification and future revenue opportunities.